EA201300244A1 - Композиции и способы для лечения сердечно-сосудистого заболевания - Google Patents

Композиции и способы для лечения сердечно-сосудистого заболевания

Info

Publication number
EA201300244A1
EA201300244A1 EA201300244A EA201300244A EA201300244A1 EA 201300244 A1 EA201300244 A1 EA 201300244A1 EA 201300244 A EA201300244 A EA 201300244A EA 201300244 A EA201300244 A EA 201300244A EA 201300244 A1 EA201300244 A1 EA 201300244A1
Authority
EA
Eurasian Patent Office
Prior art keywords
electrokinetically modified
fluids
methods
administering
electrokinetically
Prior art date
Application number
EA201300244A
Other languages
English (en)
Inventor
Ричард Л. Уотсон
Энтони Б. Вуд
Грегори Дж. Аршамбо
Original Assignee
Ревалезио Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ревалезио Корпорейшн filed Critical Ревалезио Корпорейшн
Publication of EA201300244A1 publication Critical patent/EA201300244A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Описаны способы для лечения сердечно-сосудистых заболеваний и родственных состояний и симптомов (например, сердечной аритмии, сосудистого заболевания, инфаркта миокарда, застойной сердечной недостаточности, миокардита, атеросклероза и рестеноза), включающие введение нуждающемуся в этом субъекту терапевтически эффективного количества электрокинетически измененной водной жидкости, как это описано в тексте данной заявки. В отдельных аспектах электрокинетически измененные водные жидкости включают водный ионный раствор кислородсодержащих наноструктур со стабилизированным зарядом, которые преимущественно имеют средний диаметр менее чем примерно 100 нм, что достаточно для обеспечения модуляции по меньшей мере одного потенциала клеточной мембраны и проводимости клеточной мембраны. Описаны способы введения или композиции электрокинетически измененных жидкостей (например, электрокинетически измененных обогащенных газом жидкостей и растворов) и терапевтические композиции, а также использование электрокинетически измененных водных жидкостей в хирургическом контексте, включая, но не ограничиваясь, операции, относящиеся к сердечно-сосудистой системе. Кроме того, дополнительные аспекты описывают способы измерения биологической активности электрокинетически измененных жидкостей.
EA201300244A 2010-08-13 2011-08-12 Композиции и способы для лечения сердечно-сосудистого заболевания EA201300244A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37349410P 2010-08-13 2010-08-13
US201161485071P 2011-05-11 2011-05-11
PCT/US2011/047673 WO2012021860A1 (en) 2010-08-13 2011-08-12 Compositions and methods for treating cardiovascular disease

Publications (1)

Publication Number Publication Date
EA201300244A1 true EA201300244A1 (ru) 2014-01-30

Family

ID=45564974

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300244A EA201300244A1 (ru) 2010-08-13 2011-08-12 Композиции и способы для лечения сердечно-сосудистого заболевания

Country Status (11)

Country Link
US (1) US20120039884A1 (ru)
EP (1) EP2603199A4 (ru)
JP (1) JP2013538803A (ru)
KR (1) KR20130100126A (ru)
CN (1) CN103347493A (ru)
AU (1) AU2011289176B2 (ru)
BR (1) BR112013003186A2 (ru)
CA (1) CA2808192A1 (ru)
EA (1) EA201300244A1 (ru)
MX (1) MX2013001749A (ru)
WO (1) WO2012021860A1 (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US20110075507A1 (en) * 1997-10-24 2011-03-31 Revalesio Corporation Diffuser/emulsifier
US7654728B2 (en) * 1997-10-24 2010-02-02 Revalesio Corporation System and method for therapeutic application of dissolved oxygen
US8784897B2 (en) * 2006-10-25 2014-07-22 Revalesio Corporation Methods of therapeutic treatment of eyes
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
US8784898B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of wound care and treatment
US7832920B2 (en) 2006-10-25 2010-11-16 Revalesio Corporation Mixing device for creating an output mixture by mixing a first material and a second material
JP5595041B2 (ja) 2006-10-25 2014-09-24 リバルシオ コーポレイション 酸素富化溶液を用いる、眼および他のヒト組織の治療処置の方法
US8609148B2 (en) * 2006-10-25 2013-12-17 Revalesio Corporation Methods of therapeutic treatment of eyes
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US20100009008A1 (en) * 2007-10-25 2010-01-14 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US20100303917A1 (en) * 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for treating cystic fibrosis
US20090263495A1 (en) * 2007-10-25 2009-10-22 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US20100303918A1 (en) * 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
US20100029764A1 (en) * 2007-10-25 2010-02-04 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US9745567B2 (en) * 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20100015235A1 (en) * 2008-04-28 2010-01-21 Revalesio Corporation Compositions and methods for treating multiple sclerosis
BRPI0911757A2 (pt) * 2008-05-01 2013-09-17 Revalesio Corp composiÇÕes e mÉtodos para tratar distérbios digestivos.
US20100098687A1 (en) * 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions
US20100098659A1 (en) * 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
US8815292B2 (en) * 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
JP6026998B2 (ja) 2010-05-07 2016-11-16 リバルシオ コーポレイション 生理的パフォーマンスおよび回復時間を強化するための組成物および方法
WO2012021856A1 (en) 2010-08-12 2012-02-16 Revalesio Corporation Compositions and methods for treatment of taupathy
EP3456815B1 (en) * 2016-05-13 2024-07-03 SIGMA TECHNOLOGY, Inc. Aqueous solution capable of being administered to living body, and method for producing same
US10022397B2 (en) * 2016-06-20 2018-07-17 Nobilis Therapeutics, Inc. Treatment of rheumatoid arthritis using noble gas mixtures
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
CN108310010B (zh) * 2018-04-03 2021-01-12 中国科学院上海硅酸盐研究所 一种能够用于治疗心肌梗死的离子试剂及其制备方法和应用
EP3801468A4 (en) * 2018-05-25 2022-03-09 Revalesio Corporation INHIBITION OF NEUROLOGICAL DISEASE
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
WO2020047394A1 (en) * 2018-08-31 2020-03-05 The Trustees Of The University Of Pennsylvania Injectable hydrogels for local delivery to the heart
EP3991746A4 (en) * 2019-06-26 2023-08-09 Takeda Pharmaceutical Company Limited TRANSFECTION PROCESS
JP6760630B1 (ja) * 2019-10-29 2020-09-23 学校法人 愛知医科大学 微小気泡含有電解質液の製造方法および微小気泡含有電解質液の調製に用いる微小気泡含有溶媒の製造方法
CA3191727A1 (en) * 2020-08-14 2022-02-17 Mayo Foundation For Medical Education And Research Methods and materials for tissue ablation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5595041B2 (ja) * 2006-10-25 2014-09-24 リバルシオ コーポレイション 酸素富化溶液を用いる、眼および他のヒト組織の治療処置の方法
US7544365B2 (en) * 2006-12-14 2009-06-09 The Hospital For Sick Children TRPV1+ sensory neurons control of β-cells stress and islet inflammation in diabetes
US20100008997A1 (en) * 2007-10-25 2010-01-14 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
CA2703672A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20100015235A1 (en) * 2008-04-28 2010-01-21 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US9745567B2 (en) * 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US20100098659A1 (en) * 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
JP2011001271A (ja) * 2009-06-16 2011-01-06 Tomio Ota 輸液

Also Published As

Publication number Publication date
MX2013001749A (es) 2014-03-05
KR20130100126A (ko) 2013-09-09
WO2012021860A1 (en) 2012-02-16
AU2011289176B2 (en) 2015-09-24
JP2013538803A (ja) 2013-10-17
BR112013003186A2 (pt) 2016-06-07
CN103347493A (zh) 2013-10-09
EP2603199A1 (en) 2013-06-19
US20120039884A1 (en) 2012-02-16
AU2011289176A1 (en) 2013-03-28
EP2603199A4 (en) 2014-01-01
CA2808192A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
EA201300244A1 (ru) Композиции и способы для лечения сердечно-сосудистого заболевания
Sabbah et al. Nitroxyl (HNO) a novel approach for the acute treatment of heart failure
Nishinaka et al. Singlet oxygen is essential for neutrophil extracellular trap formation
EA201100440A1 (ru) Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
EA201391521A1 (ru) Композиции и способы для ингибирования и/или модулирования эффекторных t-клеток, участвующих в воспалительном нейродегенеративном заболевании
SG10201803833WA (en) Heterocyclic compounds useful in the treatment of disease
EA201171197A8 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
EA200970791A1 (ru) N-АДАМАНТИЛБЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ 11-β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
Zong et al. Oxygen-vacancy-rich molybdenum carbide MXene nanonetworks for ultrasound-triggered and capturing-enhanced sonocatalytic bacteria eradication
WO2010091051A3 (en) Therapeutic use of specialized endothelial progenitor cells
RU2012107483A (ru) Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек
EA201100143A1 (ru) Длительное лечение клинически выраженной сердечной недостаточности
AR069548A1 (es) Sales de propionato de 3-(2,2,2- trimetilhidrazinio ) en el tratamiento de la enfermedad cardiaca isquemica y uso medico
RU2009103367A (ru) Способ оценки эффективности лечения ишемической болезни сердца
Gradinger et al. Toxic myocarditis due to oral ingestion of hydrofluoric acid
DE602006019842D1 (de) Verwendung von lecithin als arzneimittel zur behandlung von psoriasis
Mirkabilovich et al. The effectiveness of ACE inhibitors and sartans patients with acute myocardial infarction in the elderly on a distant stage monitoring
Payne et al. The Matrikine Acetylated Proline-Glycine-Proline (acpgp) Couples Extracellular Matrix Fragmentation To Pulmonary Microvascular Remodeling And Pulmonary Hypertension
Epa et al. A62 LUNG FIBROSIS: FIBROBLAST BIOLOGY: Tissue Transglutaminase, A Two-Edged Sword: Epithelial Tg2 Expression Inhibits Myofibroblast Differentiation Via Prostaglandin (pg) E2
JP2016190833A (ja) 水素分子による乾癬患者における皮膚関節症状およびサイトカイン改善作用
Ghanta et al. Autophagy Deficient Mesenchymal Stromal Cells Are More Susceptible To Oxidative Injury And Less Effective In A Murine Model Of Sepsis
UA107787C2 (ru) Способ оценки эффективности лечения s-метопрололом больных ишемической болезнью сердца с стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическом" типа